Increased Plasma Levels of ACE and Ang II in Prediabetes May Contribute to Adipose Tissue Dysfunction
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26125517 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Bongeka Cassandra Mkhize und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban 3629, KwaZulu-Natal, South Africa. Hauptthemen laut MEDLINE: Prediabetic State, Adipose Tissue, Angiotensin II, Peptidyl-Dipeptidase A. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation, College of Health Science (CHS) of the University of KwaZulu-Natal (UKZN).
Abstract (Originalsprache)
Adipose tissue is essential for the regulation of insulin sensitivity and cytokine production, which are key processes in maintaining metabolic homeostasis. Previous studies have shown a link between the renin–angiotensin system (RAS) and adipose tissue dysfunction in type 2 diabetes (T2D); however, the role of RAS in prediabetes remains underexplored. This study aimed to analyze the association between RAS components and adipose tissue dysfunction in the prediabetic state. This observational, cross-sectional study was conducted between 21/05/21 and 20/05/24 and analyzed RAS markers in plasma samples. This study was conducted at King Edward Hospital, focusing on individuals from outpatient clinics. The study included non-prediabetic (NPD), prediabetic (PD), and T2D individuals (n = 40 per group) aged 25–45 years. The participants were selected based on fasting blood glucose levels and HbA1c criteria. Plasma RAS markers and adipose function markers were measured in each participant. Primary outcomes included HOMA-IR, HbA1c, and plasma levels of ACE1, Ang II, ACE2, Ang 1-7, adiponectin, adipsin, MCP-1, and HDL. PD participants had significantly altered glycaemic control (HOMA-IR: 2.1 ± 0.4 vs. 3.9 ± 0.8; HbA1c: 4.9 ± 0.4 vs. 5.9 ± 0.6) compared to NPD. Plasma ACE1 (162.0 ± 10.55 vs. 180.3 ± 7.546) and Ang II (20.26 ± 2.404 vs. 25 ± 1.752) were elevated, while adiponectin (29.08 ± 5.72 vs. 23.22 ± 4.93) and HDL (1.01 ± 0.11 vs. 0.67 ± 0.11) were reduced in PD. Alterations in RAS manifest early in prediabetes and are associated with adipose tissue dysfunction. These findings suggest that RAS dysregulation contributes to early metabolic disturbances in prediabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban 3629, KwaZulu-Natal, South Africa.
- Department of Human Physiology, University of KwaZulu-Natal, Westville 4000, KwaZulu-Natal, South Africa.
- Department of Pharmacology, University of Rhodes, Grahamstown 4000, Eastern Cape, South Africa.
ORCID-Profile: Palesa Mosili, Ntethelelo Hopewell Sibiya, Andile Khathi
Förderung
- National Research Foundation
- College of Health Science (CHS) of the University of KwaZulu-Natal (UKZN)
Zitieren
APA
Mkhize, B. C., Mosili, P., Ngubane, P. S., Sibiya, N. H., & Khathi, A. (2025). Increased Plasma Levels of ACE and Ang II in Prediabetes May Contribute to Adipose Tissue Dysfunction. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125517
Vancouver
Mkhize BC, Mosili P, Ngubane PS, Sibiya NH, Khathi A. Increased Plasma Levels of ACE and Ang II in Prediabetes May Contribute to Adipose Tissue Dysfunction. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125517
BibTeX
@article{Mkhize2025,
author = {Mkhize, Bongeka Cassandra and Mosili, Palesa and Ngubane, Phikelelani Sethu and Sibiya, Ntethelelo Hopewell and Khathi, Andile},
title = {Increased Plasma Levels of ACE and Ang II in Prediabetes May Contribute to Adipose Tissue Dysfunction},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26125517}
}
EUVIMED